Deepali Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10830580/publications.pdf

Version: 2024-02-01

29	660	471509 17	580821 25
papers	citations	h-index	g-index

29	29	29	942
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	â€œA LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetesâ€. Molecular Metabolism, 2021, 46, 101128.	6.5	27
2	Role of Growth Hormone in Ghrelinâ€™s Metabolic Actions. Journal of the Endocrine Society, 2021, 5, A553-A553.	0.2	0
3	High Coexpression of the Ghrelin and LEAP2 Receptor GHSR With Pancreatic Polypeptide in Mouse and Human Islets. Endocrinology, 2021, 162, .	2.8	14
4	Ghrelin cellâ€“expressed insulin receptors mediate meal- and obesity-induced declines in plasma ghrelin. JCI Insight, 2021, 6, .	5.0	10
5	Disrupting the ghrelin-growth hormone axis limits ghrelin's orexigenic but not glucoregulatory actions. Molecular Metabolism, 2021, 53, 101258.	6.5	22
6	LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue. Molecular Metabolism, 2021, 53, 101327.	6.5	37
7	Acyl-ghrelin Is Permissive for the Normal Counterregulatory Response to Insulin-Induced Hypoglycemia. Diabetes, 2020, 69, 228-237.	0.6	17
8	Ghrelin Protects Against Insulin-Induced Hypoglycemia in a Mouse Model of Type 1 Diabetes Mellitus. Frontiers in Endocrinology, 2020, 11, 606.	3.5	6
9	Î²1-adrenergic receptors mediate plasma acyl-ghrelin elevation and depressive-like behavior induced by chronic psychosocial stress. Neuropsychopharmacology, 2019, 44, 1319-1327.	5.4	23
10	Antidepressant Therapy for Depression: An Update. , 2018, , 241-255.		0
11	Ghrelin Receptor Agonist Rescues Excess Neonatal Mortality in a Prader-Willi Syndrome Mouse Model. Endocrinology, 2018, 159, 4006-4022.	2.8	20
12	5HT3 receptors: Target for new antidepressant drugs. Neuroscience and Biobehavioral Reviews, 2016, 64, 311-325.	6.1	31
13	A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system. Behavioural Brain Research, 2016, 297, 41-50.	2.2	20
14	Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice. Steroids, 2015, 96, 95-102.	1.8	47
15	Pharmacological evaluation of novel 5-HT ₃ receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery. Journal of Pharmacy and Bioallied Sciences, 2015, 7, 103.	0.6	9
16	Diabetes-associated depression: The serotonergic system as a novel multifunctional target. Indian Journal of Pharmacology, 2015, 47, 4.	0.7	52
17	Anti-anxiety effect of a novel 5-HT₃receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice. Indian Journal of Pharmacology, 2014, 46, 100.	0.7	13
18	Antidepressant-like effect of a novel 5-HT3receptor antagonist N-(benzo[d]) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (thiazol-2-yl)-3- Pharmacology and Pharmacotherapeutics, 2014, 5, 197.	0.4	7

#	Article	IF	Citations
19	QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: An approach based on behavioral and biochemical investigations. European Journal of Pharmacology, 2014, 740, 611-618.	3.5	18
20	Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety. European Journal of Pharmacology, 2014, 742, 94-101.	3.5	11
21	Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression. Acta Pharmacologica Sinica, 2014, 35, 1493-1503.	6.1	24
22	Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (quinoxalin-rodent models. European Journal of Pharmacology, 2014, 735, 59-67.	3.5	26
23	Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. Metabolic Brain Disease, 2014, 29, 701-710.	2.9	25
24	Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system. European Journal of Pharmacology, 2014, 744, 59-66.	3.5	34
25	Insulin reverses anxiety-like behavior evoked by streptozotocin-induced diabetes in mice. Metabolic Brain Disease, 2014, 29, 737-746.	2.9	43
26	Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system. Physiology and Behavior, 2014, 129, 73-78.	2.1	65
27	5HT3 receptor antagonist (ondansetron) reverses depressive behavior evoked by chronic unpredictable stress in mice: Modulation of hypothalamicâ€“pituitaryâ€“adrenocortical and brain serotonergic system. Pharmacology Biochemistry and Behavior, 2014, 124, 129-136.	2.9	30
28	Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats. Indian Journal of Psychological Medicine, 2013, 35, 290-298.	1.5	8
29	QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice. Journal of Pharmacy and Pharmacology, 2013, 66, 122-132.	2.4	21